文献速递骨软组织肉瘤与黑色素瘤

TERT启动子突变与接受BRAF和MEK抑制剂治疗的BRAF突变黑色素瘤患者更长的无进展生存期和总生存期相关

TERT promoter mutations are associated with longer progression-free and overall survival in patients with BRAF-mutant melanoma receiving BRAF and MEK inhibitor therapy.
PubMed 文献 · Eur J Cancer · 2021-12-20

该研究纳入232例接受BRAF/MEK抑制剂联合治疗的BRAF V600突变转移性或不可切除黑色素瘤患者,包括单中心回顾性发现队列(N=120)和前瞻性多中心验证队列(N=112)。结果显示TERT启动子突变患者较野生型患者PFS和OS均延长,合并队列中PFS为8.9 vs 5.5个月(HR=0.62,95%CI 0.45-0.87,P=0.004),OS为33.6 vs 17.0个月(HR=0.51,95%CI 0.35-0.75,P=0.0001)。作者认为若在更大规模研究中验证,TERT启动子突变状态应作为预测生物标志物纳入晚期黑色素瘤治疗决策。

要点

  • TERT启动子突变见于72%(N=167)的BRAF V600突变黑色素瘤患者。
  • 合并队列中TERT启动子突变 vs 野生型:PFS 8.9 vs 5.5个月(HR=0.62,95%CI 0.45-0.87,P=0.004)。
  • 合并队列中TERT启动子突变 vs 野生型:OS 33.6 vs 17.0个月(HR=0.51,95%CI 0.35-0.75,P=0.0001)。

核心结论

  • 在接受BRAF/MEK靶向治疗的黑色素瘤患者中,TERT启动子突变与更长的生存期相关。
  • 作者认为若在更大规模研究中验证,TERT启动子突变状态应作为预测生物标志物纳入晚期黑色素瘤治疗决策。

研究设计与样本

  • 研究队列共232例接受BRAF/MEK抑制剂联合治疗的转移性或不可切除BRAF V600突变黑色素瘤患者。
  • 包括单中心回顾性发现队列(N=120)和前瞻性多中心验证队列(N=112)。
  • 排除接受BRAF或MEK抑制剂辅助治疗、单药治疗或联合免疫治疗的患者。
  • 采用Kaplan-Meier分析和单因素/多因素Cox回归分析。

主要发现

  • 首次诊断中位年龄54岁(范围16-84岁),男性147/232(63.4%)。
  • 多数肿瘤携带TERT启动子突变(72%,N=167)。
  • 发现队列中TERT启动子突变 vs 野生型:mPFS 9.6个月(N=87) vs 5.0个月(N=33),HR=0.56(95%CI 0.33-0.96);mOS 33.6个月 vs 15.0个月,HR=0.47(95%CI 0.32-0.70)。
  • 验证队列中TERT启动子突变 vs 野生型:mPFS 7.3个月(N=80) vs 5.8个月(N=32),HR=0.67(95%CI 0.41-1.10);mOS 51.1个月 vs 15.0个月,HR=0.33(95%CI 0.18-0.63)。
  • 合并队列中TERT启动子突变(N=167) vs 野生型(N=65):PFS 8.9 vs 5.5个月,HR=0.62(95%CI 0.45-0.87,P=0.004);OS 33.6 vs 17.0个月,HR=0.51(95%CI 0.35-0.75,P=0.0001)。

临床怎么用

  • 作者认为若在更大规模研究中验证,TERT启动子突变状态应作为预测生物标志物纳入晚期黑色素瘤治疗决策。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Around 50% of cutaneous melanomas harbour therapeutically targetable BRAF V600 mutations. Reliable clinical biomarkers predicting duration of response to BRAF-targeted therapies are still lacking. Recent in vitro studies demonstrated that BRAF-MEK inhibitor therapy response is associated with tumour TERT promoter mutation status. We assessed this potential association in a clinical setting. METHODS: The study cohort comprised 232 patients with metastatic or unresectable BRAF V600-mutated melanoma receiving combined BRAF/MEK inhibitor treatment, including a single-centre retrospective discovery cohort (N = 120) and a prospectively collected multicenter validation cohort (N = 112). Patients were excluded if they received BRAF or MEK inhibitors in an adjuvant setting, as monotherapy, or in combination with immunotherapy. Kaplan-Meier and univariate/multivariate Cox regression analyses were performed as appropriate. RESULTS: median age at first diagnosis was 54 years (range 16-84 years). The majority of patients were men 147/232 (63.4%). Most tumours harboured TERT promoter mutations (72%, N = 167). A survival advantage was observed in both progression-free survival (PFS) and overall survival (OS) for patients with TERT promoter-mutant versus wild-type tumours in both the discovery cohort (mPFS of 9.6 months [N = 87] vs 5.0 months [N = 33]; hazard ratio [HR] = 0.56 [95% confidence interval {CI} 0.33-0.96] and mOS of 33.6 months vs 15.0 months; HR = 0.47 [95%CI 0.32-0.70]) as well as the validation cohort (mPFS of 7.3 months [N = 80] vs 5.8 months [N = 32]; HR = 0.67 [95%CI 0.41-1.10] and mOS of 51.1 months vs 15.0 months; HR = 0.33 [95%CI 0.18-0.63]). In the pooled cohort of TERT promoter-mutant (N = 167) versus wild-type (N = 65) tumours, respectively, PFS was 8.9 versus 5.5 months, (HR = 0.62; 95%CI 0.45-0.87; P = 0.004), and OS was 33.6 versus 17.0 months, (HR = 0.51; 95%CI 0.35-0.75, P = 0.0001). CONCLUSIONS: In patients with melanoma receiving BRAF/MEK-targeted therapies, TERT promoter mutations are associated with longer survival. If validated in larger studies, TERT promoter mutation status should be included as a predictive biomarker in treatment algorithms for advanced melanoma.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Thielmann CM, Matull J, Zaremba A, et al. TERT promoter mutations are associated with longer progression-free and overall survival in patients with BRAF-mutant melanoma receiving BRAF and MEK inhibitor therapy. Eur J Cancer. 2021. PMID: 34936949. doi:10.1016/j.ejca.2021.11.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。